Diffusphere technology Archives

Illustrated CareDx, Regeneron and Eupraxia representatives stand under spotlights with a DNA helix, laboratory flask and syringe, surrounded by digital medical displays and an applauding audience.

CareDx, Regeneron and Eupraxia Put Precision Medicine in the Spotlight -( $CDNA $EPRX $REGN $SNY )

by John F. Heerdink, Jr. October 31, 2026 322Views 0Likes

AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…

ive professionals meet around a conference table with laptops and calendars, beside a whiteboard highlighting December EoE data and EPRX.

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

by John F. Heerdink, Jr. October 27, 2026 359Views 0Likes

With its 120-patient target reached, encouraging early durability data and a November investor calendar, Eupraxia Pharmaceuticals is building a more substantial case for long-acting drug delivery. Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) is approaching the kind of stretch that can move a…

Scientists in a modern biotechnology laboratory review digital DNA models, molecular structures and drug development charts.

Merck’s $1.3 Billion Silence Deal Puts Precision Biotech in Focus as Serina and Eupraxia Advance -( $BBC $EPRX $IBB $MKKGY $MRK $SER $SLN $XBI )

by John F. Heerdink, Jr. October 19, 2026 409Views 0Likes

A substantial takeover premium highlights the value of differentiated medicines, while Serina Therapeutics and Eupraxia Pharmaceuticals approach clinical milestones of their own. October 19, 2026 Biotechnology investors received a rather emphatic reminder Monday that pharmaceutical innovation can still command a premium, even…

Eupraxia Pharmaceuticals illustration showing a dart hitting a 120-patient enrollment target, a December data calendar, and the EPRX stock ticker.

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

by John F. Heerdink, Jr. October 16, 2026 515Views 0Likes

With 120 patients enrolled in its Phase 2b study, Eupraxia’s drug-delivery platform moves toward a consequential clinical test. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), the story is becoming less about recruiting patients and more about what their results might reveal.…

Vintage comic-style illustration of three bulls pulling a loaded wagon through sunny farmland, with “EPRX” and “Trio of Bulls” above.

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. October 12, 2026 714Views 0Likes

Wall Street Price targets of $16, $17 and $18 seem to underscore the potential for a long-acting treatment as December clinical data approach Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has received a timely vote of confidence from three research firms, with newly…

Business analysts review Eupraxia Pharmaceuticals’ EP-104GI clinical data, including symptom reduction and histological-response visuals, alongside an investment calendar highlighting the anticipated December 2026 RESOLVE trial milestone.

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. October 2, 2026 868Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 624Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Digital Nasdaq billboard in Times Square highlighting Eupraxia Pharmaceuticals (NASDAQ: EPRX), its Nasdaq Global Select Market upgrade, and the upcoming eosinophilic esophagitis clinical-data catalyst.

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

by John F. Heerdink, Jr. September 8, 2026 351Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has moved up to the Nasdaq Global Select Market just as its lead clinical program approaches a pivotal Phase 2b interim data event. For many, the timing is rather tidy: the company is pairing greater market…

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

by John F. Heerdink, Jr. August 19, 2026 433Views 0Likes

The biotechnology market has a habit of demanding patience right up until it abruptly decides to reward it. Moderna, Inc. (NASDAQ: MRNA) recently reminded investors of that rule as enthusiasm around its personalized melanoma-vaccine program with Merck & Co., Inc. (NYSE: MRK)…

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

by John F. Heerdink, Jr. August 17, 2026 341Views 0Likes

For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…

Tag: Diffusphere technology

CareDx, Regeneron and Eupraxia Put Precision Medicine in the Spotlight -( $CDNA $EPRX $REGN $SNY )

Eupraxia: A Packed Investor Calendar Sets the Table for December EoE Data -( $EPRX $IBB $REGN $SNY $TAK $XBI )

Merck’s $1.3 Billion Silence Deal Puts Precision Biotech in Focus as Serina and Eupraxia Advance -( $BBC $EPRX $IBB $MKKGY $MRK $SER $SLN $XBI )

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

Eupraxia: Three Bullish Analyst Reports Put EP-104GI’s EoE Opportunity in Focus Post Tezspire Results -( $AMGN $APGE $AZN $EPRX $REGN $SNY $TAK )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Eupraxia Pharmaceuticals’ Nasdaq Upgrade Sets the Table for a High-Stakes EoE Catalyst -( $EPRX $SNY $XBI )

Moderna’s Melanoma Momentum Rekindles the mRNA Growth Story—and Keeps Biotech Investors Hunting for Precision -( $EPRX $XBI $MRK $MRNA )

Eupraxia Pharmaceuticals: A Precision Bet on Making Food Enjoyable Again – Meet CEO At The Tribe Event – Friday, August. 21-( $EPRX $REGN $SNY $TAK )

Your Guide To Staying Informed In The Markets